Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Newly-Formed Genesis Pharma Buys Patent on Anti-clotting Drug

publication date: Nov 12, 2007
Genesis Pharmaceuticals Enterprises completed a $5 million private placement and will use the proceeds to buy the patent on a new cerebral vascular medicine, currently undergoing testing in China. The drug, Ligustrazine Ferulic Acid Acetate (LFAA), works to reduce blood clotting and prevent platelets from clumping together. LFAA has never been imported to China nor marketed elsewhere in the world. Genesis was formed less than two months ago, when Laiyang Jiangbo Pharmaceuticals effected a reverse merger with Genesis. More details... 

Stock Symbol: (OTCBB: GTEC)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here